Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Long-Term Safety and Efficacy of Abatacept in Children With Juvenile Idiopathic Arthritis.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Ruperto, Nicolino; Lovell, Daniel J.; Quartier, Pierre; Paz, Eliana; Rubio-Pérez, Nadina; Silva, Clovis A.; Abud-Mendoza, Carlos; Burgos-Vargas, Ruben; Gerloni, Valeria; Melo-Gomes, Jose A.; Saad-Magalhães, Claudia; Chavez-Corrales, J.; Huemer, Christian; Kivitz, Alan; Blanco, Francisco J.; Foeldvari, Ivan; Hofer, Michael; Horneff, Gerd; Huppertz, Hans-Iko; Job-Deslandre, Chantal
- Source:
Arthritis & Rheumatism; Jun2010, Vol. 62 Issue 6, p1792-1802, 11p, 1 Diagram, 3 Charts, 2 Graphs
- Subject Terms:
- Additional Information
- Abstract:
The article reports the results from long-term extension (LTE) phase of a study that documented the long-term safety and efficacy of the fusion protein abatacept in children with juvenile idiopathic arthritis (JIA). Children included in study were given abatacept intravenously. Findings indicated that abatacept is effective in patients with JIC, including those who did not initially achieve ACR in Pedi 30 response during the initial 4-month open-label lead-in phase of the study.
No Comments.